Akorn (NASDAQ:AKRX) posted its earnings results on Tuesday, May 7th. The company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08, MarketWatch Earnings reports. Akorn had a negative return on equity of 13.92% and a negative net margin of 67.38%. The business had revenue of $165.90 million during the quarter, compared to analysts’ expectations of $153.01 million. The firm’s revenue was down 9.9% on a year-over-year basis. Akorn updated its FY 2019 guidance to EPS.
AKRX traded down $0.20 during trading on Thursday, hitting $3.89. 1,650,462 shares of the company’s stock traded hands, compared to its average volume of 2,692,576. The company has a market cap of $510.89 million, a price-to-earnings ratio of -10.81 and a beta of 2.60. The company has a current ratio of 3.26, a quick ratio of 2.30 and a debt-to-equity ratio of 2.31. Akorn has a 12-month low of $2.64 and a 12-month high of $19.65.
In other news, Director Steven J. Meyer purchased 10,000 shares of the stock in a transaction dated Wednesday, May 29th. The shares were purchased at an average cost of $3.75 per share, with a total value of $37,500.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have bought a total of 35,000 shares of company stock worth $139,300 over the last three months. Insiders own 3.90% of the company’s stock.
A number of research analysts have commented on AKRX shares. BidaskClub raised Akorn from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research lowered Akorn from a “hold” rating to a “sell” rating in a research report on Thursday, April 25th. Royal Bank of Canada set a $4.00 target price on Akorn and gave the stock a “hold” rating in a report on Friday, March 1st. SunTrust Banks initiated coverage on Akorn in a report on Tuesday, March 19th. They set a “hold” rating and a $4.00 target price on the stock. Finally, Piper Jaffray Companies set a $8.00 target price on Akorn and gave the stock a “buy” rating in a report on Friday, March 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. Akorn currently has an average rating of “Hold” and a consensus target price of $8.33.
Akorn Company Profile
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Featured Story: Do You Need a Fiduciary?
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.